TSE:MDP FY2025 EPS Estimate Lifted by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Leede Financial upped their FY2025 earnings per share estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leede Financial analyst D. Loe now forecasts that the company will post earnings per share of $0.29 for the year, up from their previous estimate of $0.20. Leede Financial currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

Other research analysts also recently issued reports about the stock. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Stifel Nicolaus boosted their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a buy rating and five have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Trading Up 19.0 %

MDP stock opened at C$4.75 on Thursday. The stock has a market cap of C$116.52 million, a P/E ratio of 95.00 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The company’s 50 day moving average is C$3.14 and its two-hundred day moving average is C$2.69.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.